Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04116034
Other study ID # 2019-CHF-005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 26, 2019
Est. completion date April 15, 2021

Study information

Verified date May 2021
Source Sequana Medical N.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of Heart failure subects resistant to diuretic therapy. Up to 10 subjects will be enrolled in up to 3 centres in Belgium and Georgia and will be iplanted with the alfapump DSR system. Subjects will undergo DSR titration during a 2 week hospitalisation period, and will continue titrated DSR therapy as outpatients for 4 more weeks.


Description:

Up to 10 subjects diagnosed with stable chronic heart failure (CHF) on high oral diuretic dose and an MDRD eGFR > 30ml/min/1.73m2 will undergo subcutaneous implantation of the alfapump DSR system (Day-13) and portacath system and participate in a 6 week interventional study. Prior to an inpatient study period, the subject will undergo a 40mg IV furosemide (or 1 mg IV bumetanide) diuretic challenge with timed biospecimen collection. On day 14 post-implant (Day 0), the subject will be admitted for a 14-day period in which diuretics will be withheld and subjects will be on a strict low-sodium (3g/day) diet with strict intake/output and all urine collected and samples saved for analysis. During the first 7 days (Day 0 - 6) subjects will be treated with 1000ml of DSR Infusate Monday, Wednesday, Friday administered to the peritoneal cavity through the subcutaneous peritoneal catheter. The infusate will remain in the peritoneal cavity for a 2 hour dwell time, then all fluid will be removed from the peritoneal cavity to the urinary bladder using the alfapump DSR system over the subsequent 8 hours. On day 7, subjects will be transitioned to a moderate to high salt diet given as the same low-sodium (3g/day) diet with supplementation with sodium chloride tablets (2g/day) (5g/day total sodium), as this will likely represent their typical home sodium intake. During this time, the optimal treatment protocol (frequency of administration and volume of DSR infusate administered) for individual subjects based on daily sodium balance, weight changes, and blood pressure will be created and tested over the next seven days in hospital (Day 7 - 13). Following the inpatient period, a second diuretic challenge will be conducted. Over the subsequent 28 days, diuretics will continue to be withheld with preferential maintenance of euvolemia through DSR and subjects will come into the clinic based on their tailored therapy schedule and undergo supervised DSR infusate administration. Addition of diuretic treatment will only be allowed if maximal DSR therapy has been instituted (DSR 7 days per week (i.e., including weekends) at 1.5L per session with dwell time of 4 hours) and/or holding diuretics until additional DSR can be utilized would represent a risk to the subject, as described in the CIP diuretic algorithm. After the completion of the study period, the alfapump DSR therapy is halted and the subject undergoes a third diuretic challenge to quantify diuretic response. At this point oral diuretic therapy will be resumed. At the end of the study the alfapump can remain implanted and set to 'dormant' state after discussion and agreement between subject and investigator, and if there are no clinical, ethical or other reasons indicating explanation of the alfapump. Alternatively, the subject may elect to enroll into a low intensity follow-on study.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date April 15, 2021
Est. primary completion date April 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects > 18 years of age 2. eGFR > 30ml/min/14.73m2 3. Diagnosis of heart failure with one of the following: a. nt-proBNP > 400 pg/ml (or BNP > 100 pg/mp) and oral diuretic dose = 80mg furosemide (or 20mg torsemide or 1mg bumetanide) OR b. Oral diuretic dose = 120mg furosemide (or 30 mg torsemide or 1.5 mg bumetanide) 4. Stable diuretic dose for 30 days 5. Systolic blood pressure = 100 mmHg 6. Determined by treating provider to be at optimal volume status Exclusion Criteria: Candidates for participation will be ineligible for the study if any of the following exclusion criteria apply: 1. Proteinuria > 1g/day 2. BMI > 40 3. History of abdominal surgery or peritonitis 4. Anemia with hemoglobin < 8g/dL 5. Serum sodium < 135 mEq/L 6. Severe hyperkalemia or baseline plasma potassium > 4.5 mEq/L 7. Significant other organ disease or comorbidities 8. Hospitalization within 90 days 9. Cirrhosis 10. Hemodynamically significant stenotic valvular disease 11. Active or recurrent urinary tract infection or history of renal transplant 12. History of significant bladder dysfunction expected to interfere with ability of subject to tolerate DSR pumping into bladder 13. Uncontrolled diabetes with frequent hyperglycemia or Type 1 diabetes 14. Subject is currently participating in another clinical trial 15. Subject is unable to comply with all required study follow-up procedures

Study Design


Intervention

Device:
alfapump DSR system
Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

Locations

Country Name City State
Belgium OLV Ziekenhuis Aalst
Georgia Tbilisi Heart & Vascular Clinic Tbilisi

Sponsors (2)

Lead Sponsor Collaborator
Sequana Medical N.V. Yale University

Countries where clinical trial is conducted

Belgium,  Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Other Bioimpedance Change in bioimpedance from baseline through treatment At baseline, day 7, 14, and 42
Other Hemoconcentration markers Change in hemoglobin versus hematocrit ratio from baseline through treatment At baseline, day 7, 14, and 42
Other N-Terminal Prohormone of Brain Natriuretic Peptide (nt-ProBNP) Change in nt-proBNP from basline through treatment At baseline, day 7, 14, and 42
Other Weight Change in Weight from baseline through treatment At baseline, day 7, 14, and 42
Other Glycolated Hemoglobine (HbA1c) Changes in HBA1c from baseline through treatment At baseline, day 7, 14, and 42
Other Sodium balance Daily sodium balance Up to day 42
Other Fluid balance Daily fluid balance Up to day 42
Other 6-hour diuretic response Change in response to 6 hour diuretic challenge from baseline through treatment At baseline, day 14, day 42
Primary Safety in-hospital - Device related Rate of device related serious adverse events Through Day 14 of treatment period
Primary Safety in-hospital - therapy related Rate of therapy related serious adverse events Through Day 14 of treatment period
Primary Safety in-hospital - procedure related Rate of procedure related serious adverse events Through Day 14 of treatment period
Primary Safety during treatment period - device related Rate of device related serious adverse events through Day 42 of treatment period
Primary Safety during treatment period - procedure related Rate of procedure serious adverse events through Day 42 of treatment period
Primary Safety during treatment period - therapy related Rate of therapy related serious adverse events through Day 42 of treatment period
Secondary Feasibiity endpoint sodium balance in-hospital Number of patients with neutral sodium balance (sodium intake equal to sodium output) in the absence of diuretic therapy during hospitalization period through Day 14 of DSR therapy
Secondary Feasibility endpoint sodium balance during treatment period Number of patients with neutral sodium balance (sodium intake equal to sodium output) in the absence of diuretic therapy in a titrated schedule during treatment period Through Day 42 of DSR Therapy
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy